Research Associate

Position Overview:

Acrivon Therapeutics/AB is seeking a highly motivated Research Associate to join our Proteomic and Drug Discovery team at Acrivon AB, located in Medicon Village, Lund. The successful candidate will be engaged in research of therapeutic agents and biomarkers for our portfolio of drug development programs in oncology. The candidate will support, perform and develop assays for drug profiling, using proteomics and phosphoproteomics in cell lines, animal models and patient samples.
Duties & Responsibilities
Support all ongoing research projects with cell culture, protein assays, drug MoA assays, and proteomic profiling
Develop and perform robust cell-based assays for drug profiling
Support general lab duties, organization and activities
Comply with all applicable regulations; Ensure that work performed in area of responsibility is conducted in a safe and compliant manner; Maintain proper records in accordance with SOPs and policies.
Prepare clear technical reports and communicate results and plans on a regular basis

Requirements:
M.S. in Biological Sciences or in a related discipline
2-3 years of laboratory experience in academic research or in industry, experience in cancer research is highly desirable
Broad molecular biology laboratory skills including cell-based assays, microscopy, Western Blot, PCR, etc.
Knowledge and experience in working with cancer cell lines and models, as well as signaling pathways in tumor biology
Experience in drug development and proteomic profiling in cancer models
Excellent communication, organizational skills and working knowledge of Microsoft Office
Ability to work independently and as a team member in a fast-paced environment
Fluent in English

About Acrivon Therapeutics:

Acrivon Therapeutics is a personalized oncology company specialized in accelerated drug development using a unique, proprietary proteomics-based patient selection platform, called AP3. Their unbiased method is widely applicable across the majority of cancers that do not harbor single gene driver mutations, and specifically applied to oncology drugs to enable development in well-defined patient responders in attractive indications. Selected drugs are developed in response-predictive trials using a quantitative predictive and pharmacodynamic protein biomarker signature derived from AP3. The experienced, founding team has pioneered and proven all the required technologies and platforms.